Lower Sooner: What the 2026 Cholesterol Guidelines Mean for You

2026 Cholesterol Guidelines: LDL, Lp(a) and ApoB

Many people remember being told that their cholesterol was “a little high”.

The harder questions often come next. High compared with what? Does one number tell the whole story? Is food the main issue? Should you have another test? And does a result that looked acceptable ten years ago still deserve attention now?

The 2026 American College of Cardiology and American Heart Association guideline on dyslipidaemia takes a broader approach. Its central message is sometimes summarised as “lower sooner”: reduce prolonged exposure to artery-damaging lipoproteins earlier, while tailoring decisions to the person rather than treating every cholesterol result the same way.

This is a United States guideline, not a universal rulebook. Countries use different risk calculators, treatment thresholds and healthcare pathways. Even so, several of its themes—including risk-based LDL targets, once-in-adulthood lipoprotein(a) testing and selective use of coronary calcium imaging—also appear in recent European guidance. The overall direction is clear: cholesterol care is becoming earlier, more personalised and more detailed.

What Are the 2026 Cholesterol Guidelines?

The guideline was published in March 2026 and replaces the 2018 US blood cholesterol guideline.

Its new title is important. Instead of focusing only on cholesterol, it addresses dyslipidaemia—an umbrella term for unhealthy levels of fats, cholesterol-carrying particles or related lipoproteins in the blood. This includes high LDL cholesterol, high triglycerides and elevated lipoprotein(a), often written as Lp(a).

The guideline brings together risk assessment, testing, lifestyle support, medicines and monitoring across different ages and levels of cardiovascular risk. It also reflects an important shift in thinking: the amount of time a person is exposed to atherogenic, or plaque-forming, particles matters—not only the result on their latest blood test.

What Does Dyslipidaemia Mean?

Cholesterol and triglycerides cannot travel freely through the bloodstream. They are carried inside particles called lipoproteins.

A standard cholesterol panel commonly reports:

• Total cholesterol: The overall amount of cholesterol measured in the blood

• LDL cholesterol: Cholesterol carried mainly in low-density lipoprotein particles

• HDL cholesterol: Cholesterol carried in high-density lipoprotein particles

• Triglycerides: A form of fat used and stored for energy

• Non-HDL cholesterol: Total cholesterol minus HDL cholesterol, capturing cholesterol in several potentially atherogenic particle types

These figures are useful, but they do not always reveal the complete picture. Two people can have the same LDL cholesterol result while having different numbers of cholesterol-carrying particles, different inherited risks and different evidence of plaque in their arteries.

That is why the updated guideline gives more attention to tests such as Lp(a), apolipoprotein B and coronary artery calcium scoring.

Why Is “Lower Sooner” the Main Message?

A cholesterol test is a snapshot. Atherosclerosis develops more like a long film.

LDL-containing particles can enter the artery wall and contribute to plaque formation over time. The risk is influenced by both the level of exposure and how long that exposure continues. A moderately raised LDL level present for decades may matter even when a person feels well and has never had a heart problem.

The new guideline therefore places greater emphasis on discussing risk earlier rather than waiting until someone is older, symptoms appear or a cardiovascular event occurs.

This does not mean that every adult needs cholesterol-lowering medicine or the same LDL target. It means that clinicians are encouraged to consider lifetime exposure, family history, blood pressure, diabetes, kidney health, smoking, age and other risk markers together.

What Has Changed in the New Guideline?

The changes can be grouped into six practical ideas:

1. Risk assessment begins earlier and looks further ahead.

2. LDL and non-HDL treatment goals are back.

3. Lp(a) testing is recommended at least once in adulthood.

4. ApoB testing may clarify risk in selected people.

5. Coronary artery calcium scans have a larger role when treatment decisions are uncertain.

6. Medical, family and reproductive history receive more attention.

Each of these changes answers a different question. Together, they aim to replace the one-number approach with a more complete cardiovascular risk picture.

What Is the New “CPR” Approach to Risk?

The guideline uses a memorable three-part model: Calculate, Personalise and Reclassify.

Calculate

For suitable adults without known atherosclerotic cardiovascular disease, US clinicians may use the American Heart Association’s PREVENT equations to estimate the chance of a heart attack or stroke over the next ten years and, for younger adults, over a longer period.

PREVENT considers information such as age, sex, blood pressure, cholesterol, smoking, diabetes, kidney function and whether certain medicines are already being used.

It was developed using data from millions of US adults. Other countries may use different validated tools, such as SCORE2 or SCORE2-OP in parts of Europe. An online calculator should not be treated as a diagnosis or used to start or stop medicine without professional interpretation.

Personalise

A risk score cannot include every important detail.

The guideline asks clinicians to consider factors that may raise concern even when the calculated risk appears modest. These may include:

• A family history of premature heart disease or stroke

• Elevated Lp(a)

• Chronic inflammatory conditions

• Persistently raised high-sensitivity C-reactive protein

• Certain ethnic backgrounds associated with higher cardiovascular risk

• Pregnancy-related conditions such as pre-eclampsia, gestational hypertension or gestational diabetes

• Preterm delivery

• Premature or early menopause

• Polycystic ovary syndrome

For a woman now in her 50s, 60s or 70s, a pregnancy complication from decades ago can still be relevant to today’s cardiovascular assessment. That history is worth mentioning even if it is not automatically shown in a current medical record.

Reclassify

When the decision about treatment remains uncertain, another test may move a person into a clearer risk category.

The main example is a coronary artery calcium scan. Evidence of calcified plaque can support more active cholesterol management, while a score of zero may sometimes support delaying medicine in a lower-risk person who has no major competing risk factors.

Reclassification is not the same as screening everyone. The extra test should answer a genuine clinical question.

What Do the New LDL Targets Mean?

Earlier US guidance focused heavily on the percentage by which LDL cholesterol was reduced. The 2026 guideline keeps percentage reduction important but also brings back absolute LDL and non-HDL treatment goals.

The table below shows examples from the US guideline. They are not universal targets and should not be applied without considering a person’s diagnosis, risk and local clinical guidance.

Situation in the 2026 US guideline	Example LDL-C goal	Example non-HDL-C goal
Borderline or intermediate risk, before a first cardiovascular event	Below 100 mg/dL, approximately 2.6 mmol/L	Below 130 mg/dL, approximately 3.4 mmol/L
High ten-year risk, before a first cardiovascular event	Below 70 mg/dL, approximately 1.8 mmol/L	Below 100 mg/dL, approximately 2.6 mmol/L
Established ASCVD with very high risk of another event	Below 55 mg/dL, approximately 1.4 mmol/L	Below 85 mg/dL, approximately 2.2 mmol/L

The lower target for someone with established disease reflects a higher starting risk. The potential benefit of lowering LDL is generally greater when the likelihood of another heart attack, stroke or other atherosclerotic event is already high.

Your target may differ because of your country’s guideline, age, medical history, test results, treatment tolerance and personal preferences.

Why Measure Non-HDL Cholesterol as Well as LDL?

LDL cholesterol is still the main treatment marker, but it is not the only cholesterol carried in potentially harmful particles.

Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. It includes cholesterol carried in LDL and several triglyceride-rich remnant particles.

This can be particularly useful when triglycerides are raised. Because non-HDL cholesterol usually appears on a standard lipid report or can be calculated from it, it adds information without requiring a separate specialised test.

What Is Lipoprotein(a), or Lp(a)?

Lp(a) is an LDL-like particle with an additional protein attached to it. Its level is largely determined by genetics and often remains relatively stable across adulthood.

The 2026 guideline recommends measuring Lp(a) at least once in adulthood. The 2025 European dyslipidaemia updatealso supports considering a once-in-adulthood measurement, making this one of the more internationally consistent developments.

A standard cholesterol panel usually does not include Lp(a). It must be ordered separately.

The US guideline considers an Lp(a) level of at least 125 nmol/L or 50 mg/dL a risk-enhancing result. Levels around 250 nmol/L or 100 mg/dL are associated with a still greater estimated risk.

There is an important catch: laboratories report Lp(a) in either nmol/L or mg/dL, and there is no exact universal conversion between the two because Lp(a) particles vary in size. Interpret the result in the unit your laboratory provides rather than trying to convert it yourself.

What Happens If Lp(a) Is High?

A high result does not mean that a heart attack is inevitable.

Lifestyle changes usually have little direct effect on Lp(a) itself, but they can still reduce overall cardiovascular risk by supporting blood pressure, blood sugar, weight, fitness and other cholesterol measures. A clinician may also place greater emphasis on lowering LDL cholesterol and managing other risk factors.

Because Lp(a) is strongly inherited, close relatives may sometimes be advised to have their level checked as well.

What Is ApoB, and Why Might It Be Useful?

Apolipoprotein B, or ApoB, is a structural protein found on the main atherogenic lipoprotein particles.

A simple analogy can help:

• LDL cholesterol estimates how much cholesterol cargo is being carried.

• ApoB gives a closer estimate of how many atherogenic vehicles are carrying that cargo.

A person can have an LDL cholesterol result that appears acceptable but still have a relatively high number of particles. This mismatch is more likely in people with raised triglycerides, type 2 diabetes, metabolic syndrome or certain patterns of cardiovascular-kidney-metabolic risk.

The new guideline does not say that everyone needs ApoB testing. It suggests using it selectively when a standard lipid panel may underestimate remaining risk or when LDL and non-HDL targets have been reached but uncertainty remains.

What Is a Coronary Artery Calcium Scan?

A coronary artery calcium, or CAC, scan is a specialised non-contrast CT scan that looks for calcium within plaque in the coronary arteries.

The score does not measure cholesterol in the blood. It looks for evidence that calcified atherosclerotic plaque is already present.

The 2026 US guideline gives CAC a stronger role for men aged 40 and over and women aged 45 and over when ten-year risk is borderline or intermediate and the decision about cholesterol-lowering medicine remains uncertain.

A higher score generally supports more intensive risk reduction. A score of zero may allow some lower-risk people to defer statin therapy, provided they do not have other major conditions or risk enhancers that change the decision.

CAC scanning is not a routine test for everyone. It involves radiation, does not show every type of plaque and is usually unnecessary when a person already has known atherosclerotic cardiovascular disease or when the treatment decision is already clear.

Which Health Conditions Change the Cholesterol Conversation?

The guideline recommends lipid-lowering therapy for primary prevention in adults aged 40 to 75 with certain higher-risk conditions, including:

• Type 1 or type 2 diabetes

• Stage 3 or stage 4 chronic kidney disease

• HIV

These conditions can increase cardiovascular risk even when LDL cholesterol is not dramatically raised.

Cancer treatment, familial hypercholesterolaemia, high triglycerides and established cardiovascular disease also require more specialised decisions. The correct plan may involve a cardiologist, lipid specialist, kidney specialist, diabetes team, pharmacist or another clinician familiar with the person’s wider health needs.

Why Does This Matter More After 50?

By the time many people reach their 50s, they have accumulated decades of exposure to cholesterol, blood pressure, smoking, diabetes, inactivity or other risk factors.

This does not make heart disease inevitable. It does make a fuller review more useful than simply comparing this year’s total cholesterol with last year’s.

Questions become especially relevant after 50:

• Have your LDL and non-HDL levels been raised for many years?

• Has anyone in your close family had early heart disease or stroke?

• Have you ever had Lp(a) measured?

• Do you have diabetes, kidney disease, high blood pressure or an inflammatory condition?

• For women, was there a history of pre-eclampsia, gestational diabetes, preterm birth or early menopause?

• Would a coronary calcium scan actually change the treatment decision?

• Are several medicines or health conditions affecting what is practical and safe?

For adults over 75, the guideline stresses that treatment decisions should not be based on age alone. Functional ability, frailty, other illnesses, medicine burden, personal priorities and likely benefit all belong in the discussion.

Does Everyone Now Need a Statin?

No.

The guideline supports earlier conversations about lipid-lowering treatment, but it still relies on individual risk, shared decision-making and response to lifestyle measures.

Statins remain the foundation of medication treatment for many people because they have extensive evidence for reducing cardiovascular events in appropriate patients. If LDL goals are not reached, or if a person cannot tolerate the recommended statin plan, a clinician may consider other evidence-based medicines such as ezetimibe, bempedoic acid or a PCSK9 inhibitor.

The choice depends on how much LDL reduction is needed, existing cardiovascular disease, other medical conditions, possible side effects, cost, availability and patient preference.

Do not stop or reduce prescribed cholesterol medicine because of a new article, a single test result or a concern about side effects. Discuss the problem with the prescriber or pharmacist. A different dose, schedule or medicine may be possible.

What Has Not Changed?

The more sophisticated tests do not replace the basics.

The guideline continues to support:

• A varied eating pattern centred on vegetables, fruit, whole grains, beans, nuts, seeds, unsaturated fats and suitable lean protein sources

• Limiting ultra-processed foods high in saturated fat, added sugar and sodium

• Regular physical activity suited to health and ability

• Avoiding tobacco products

• Maintaining a weight that supports overall health

• Managing blood pressure and diabetes

• Prioritising restful sleep

• Taking prescribed medicine as directed

Lifestyle changes can improve LDL cholesterol, triglycerides and wider cardiovascular health. They may not fully overcome inherited conditions such as familial hypercholesterolaemia or high Lp(a), which is why some people need medicine despite already living carefully.

The guideline’s patient materials also state that dietary supplements are not recommended as a substitute for evidence-based cholesterol management. Tell your healthcare professional about any supplements you use, as some can interact with medicines or affect other health conditions.

What Should You Do With Your Next Cholesterol Result?

Rather than asking only, “Is my cholesterol high?”, try asking, “What does this result mean in the context of my overall risk?”

A practical review may include:

1. Checking the full lipid panel rather than total cholesterol alone.

2. Comparing the result with previous years to look for long-term patterns.

3. Reviewing blood pressure, diabetes status, kidney function, smoking and family history.

4. Asking whether a once-in-adulthood Lp(a) test has been done.

5. Considering ApoB only when it is likely to add useful information.

6. Discussing a CAC scan only if the result would change an uncertain treatment decision.

7. Agreeing on a personal target and follow-up plan.

The most useful outcome is not simply a lower number on paper. It is a clear, realistic plan that matches your actual cardiovascular risk.

Questions to Ask Your Doctor

You may wish to ask:

• What is my overall risk of heart attack or stroke, not just my cholesterol result?

• Which risk calculator is recommended in my country?

• What LDL and non-HDL targets are appropriate for me?

• How have my cholesterol results changed over time?

• Have I ever had an Lp(a) test, and would one be useful?

• Would ApoB add meaningful information in my case?

• Would a coronary artery calcium scan change what you recommend?

• Does my family history suggest an inherited cholesterol condition?

• Are past pregnancy complications or early menopause relevant to my risk?

• How do my blood pressure, blood sugar and kidney function affect the plan?

• What lifestyle change is likely to make the greatest practical difference for me?

• If I have medicine side effects, what alternatives can we discuss?

• When should my blood tests and treatment plan be reviewed again?

Take an up-to-date list of medicines and supplements, along with any older cholesterol results you can access. A trend over time can be more informative than one isolated reading.

The Bottom Line

The 2026 cholesterol guidelines move the conversation beyond a single LDL result.

Their main themes are earlier attention to lifetime exposure, personalised risk assessment, the return of LDL and non-HDL goals, once-in-adulthood Lp(a) testing, selective ApoB testing and greater use of coronary calcium scoring when decisions remain uncertain.

For adults in their 50s and beyond, the practical message is not to chase the lowest number without context. It is to understand your full risk profile, know which tests are genuinely useful and agree on a plan with a qualified healthcare professional.

The guideline is American, and local recommendations vary. But the wider lesson travels well: the earlier your risk is understood, the more opportunity there may be to manage it thoughtfully.

Related AtheroCare Reading

Cholesterol Isn’t Just About What’s on Your Plate — The Tests That Matter Most

Learn what a standard lipid panel shows and why other cardiovascular tests may sometimes add useful context.

Family History of Heart Disease: What It Means and How to Lower Your Risk

Understand how inherited factors can influence cardiovascular risk without determining your future.

Understanding Calcium Scores

Explore what a coronary artery calcium score measures and which questions to discuss before having the scan.

Do I Have to Take Statins Forever?

Learn why long-term statin decisions depend on the reason for treatment, personal risk and professional review.

Healthy Fats vs. Unhealthy Fats: A Heart-Health Guide

See how the type of fat in your eating pattern can matter more than avoiding all dietary fat.

References

American College of Cardiology: Lower Sooner—How the 2026 Dyslipidemia Guideline Changes Practice

American Heart Association: 2026 Guideline on the Management of Dyslipidemia

American Heart Association: Top Things to Know—Guideline on the Management of Dyslipidemia

American College of Cardiology: ACC/AHA Issue Updated Guideline for Managing Lipids and Cholesterol

American Heart Association: Key Patient Messages—2026 Dyslipidemia Guideline

American Heart Association: Lipoprotein(a)

European Society of Cardiology: What Is New in the 2025 Dyslipidaemia Update?

American Heart Association: Take-Home Messages for Geriatric Clinicians

Medical Disclaimer

This article is provided for general information and education only. It is not intended to provide medical advice, diagnosis or treatment.

Always speak with a qualified healthcare professional about symptoms, medicines, supplements, test results and your personal cardiovascular risk. Do not begin, stop or change any treatment based only on information in this article.